Located in Milwaukee, Wisconsin, the Versiti Blood Research Institute (VBRI) is the largest blood-focused research institute in the United States. With over 30 basic, translational, and clinical researchers, the institute is dedicated to advancing scientific knowledge and developing innovative therapies related to blood and blood disorders. The institute's research interests encompass a wide range of topics, including transfusion medicine, cellular therapy, thrombosis/hemostasis, immunology, and hematologic malignancies. As a vital part of Versiti, a non-profit organization with a blood bank at its core, the VBRI strives to improve lives through innovative research and the development of novel diagnostics and treatments.
VBRI is part of the Milwaukee Regional Medical Campus, a rapidly growing clinical-translational research hub. VBRI’s proximity to the Medical College of Wisconsin, Childrens’ Hospital of Wisconsin, and Froedtert Hospital facilitates seamless interdisciplinary collaborations. A range of exemplary core facilities support highly competitive research. In the summer of 2024, construction of a new research building will start, doubling existing VBRI research space to enable the recruitment of 10-15 new faculty. With its renowned researchers, strategic expansion plans and location in a highly collaborative environment, the VBRI is poised to maintain and expand its position as one of the leading hematology institutes in the world.
Under the direction of a Principal Investigator, further develops and expands understanding of scientific theory in his/her area of interest. Incumbent also learns and applies scientific laboratory techniques and gains experience in other areas of research that will lead to increased probability of success as an independent scientist. This is a training position with an expected duration of 1 – 3 years. The DIMENSIONS section is used only on position descriptions for supervisors, managers, or vice presidents.
Dr. Joshua Muia’s research interests include Metalloproteases (mainly the ADAMTS family) that are involved in the pathogenesis of cardiovascular disease, ADAMTS13 testing in Thrombotic Thrombocytopenia Purpura (TTP), and the role of von Willebrand factor (VWF) in thrombotic/bleeding disorders. Dr. Muia is also interested in developing and optimizing fluorogenic substrates for enzymes of clinical significance. The major projects being pursued are:
Education
Experience
Knowledge, Skills and Abilities
Tools and Technology
#LI-Onsite
#LI-EH1
#VBRI